BRCA2 and breast cancer: As detailed below, both were identified as candidate genes through a whole-exome sequencing (WES) approach applied to multiple breast cancer families not known to carry pathogenic mutations in BRCA1 and BRCA2. Further evidence was subsequently sought using case-control analyses (summarized in Additional file 1: Table S1).